Polatuzumab Vedotin-piiq and Viekira Pak
Determining the interaction of Polatuzumab Vedotin-piiq and Viekira Pak and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration with potent inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with ketoconazole, a potent CYP450 3A4 inhibitor, is predicted to increase unconjugated MMAE exposure (AUC) by 45% according to the product labeling. The risk and/or severity of toxicities of polatuzumab vedotin may increase. MANAGEMENT: Caution is advised when polatuzumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling. References "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Professional:MONITOR CLOSELY: Coadministration with potent inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. MMAE is a substrate for CYP450 3A4. Concomitant use of polatuzumab vedotin with ketoconazole, a potent CYP450 3A4 inhibitor, is predicted to increase unconjugated MMAE exposure (AUC) by 45% according to the product labeling. The risk and/or severity of toxicities of polatuzumab vedotin may increase.
MANAGEMENT: Caution is advised when polatuzumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.
- "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.
Generic Name: polatuzumab vedotin
Brand name: Polivy
Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira Pak, Viekira XR
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Polatuzumab Vedotin-piiq-Viekira XR
- Polatuzumab Vedotin-piiq-Vienva
- Polatuzumab Vedotin-piiq-Vigabatrin
- Polatuzumab Vedotin-piiq-Vigabatrin Oral Solution
- Polatuzumab Vedotin-piiq-Vigabatrin Tablets
- Polatuzumab Vedotin-piiq-Vigadrone
- Viekira Pak-Polio vaccine, inactivated
- Viekira Pak-Poliovirus Vaccine (Inactivated)
- Viekira Pak-Poliovirus vaccine, inactivated Injection
- Viekira Pak-Polivy
- Viekira Pak-Polmon
- Viekira Pak-Polocaine